期刊文献+

胃癌组织中CXCR3表达与微血管形成的关系及其临床意义 被引量:11

Correlation of CXCR3 expression with angiogenesis and its significance in gastric cancer
下载PDF
导出
摘要 目的探讨胃癌组织中CXCR3的表达和微血管形成的关系并分析其临床意义。方法采用免疫组化法检测169例胃癌组织中CXCR3蛋白表达和肿瘤间质微血管密度(microvascular density,MVD),分析其相关性及其与胃癌临床病理参数的关系。结果 CXCR3表达在分化程度高(P=0.025)、浸润程度浅(P=0.005)、TNM分期低(P=0.002)及无淋巴结转移(P=0.001)的胃癌患者中更高;MVD在胃癌分化程度低者中更高(P=0.001),与浸润深度、TNM分期及淋巴结转移无关(P>0.05)。胃癌组织中CXCR3表达与MVD呈负相关(r=-0.151,P=0.049)。Kaplan-Meier分析发现高表达CXCR3的胃癌患者(P=0.015)和低MVD患者(P=0.047)的生存时间延长。结论胃癌中CXCR3的表达与MVD呈负相关,且与胃癌的浸润、转移相关。 Purpose To explore the correlation between chemokine receptor CXCR3 expression with angiogenesis in gastric cancer (GC) and to analyze its significance. Methods The expression of CXCR3 in tumor cells and microvascular density (MVD) in tumor stroma were detected in 169 GC tissues by immunohistochemical (IHC) staining. The relationship between CXCR3 expression and MVD, and correlation with clinical pathological factors were analyzed. Result CXCR3 expression was inversely associated with dif- ferentiation ( P = 0. 025 ), invasion ( P = 0. 005 ), TNM stage ( P = 0. 002 ) and lymph nodes metastasis ( P = 0. 001 ). MVD was high- er in poorly-differentiated GC tissues (P = 0. 001 ), while not correlated with invasion, TNM stage and lymph nodes metastasis (all P 〉0. 05). What' s more, the expression of CXCR3 was negative associated with MVD (r = -0. 151, P =0. 049). Kaplan-Meier anal- ysis indicated that high expression of CXCR3 and low MVD were associated with improved overall survival (OS) ( Log-rank, P = 0. 015 and P = 0. 047, respectively). Conclusion CXCR3 expression and MVD are negative correlation, and are associated with GC inva- sion and metastasis.
作者 李凯 刘杰
出处 《临床与实验病理学杂志》 CAS CSCD 北大核心 2016年第10期1097-1100,共4页 Chinese Journal of Clinical and Experimental Pathology
关键词 胃肿瘤 CXCR3 CD34 微血管密度 gastric neoplasm CXCR3 CD3g microvascular density
  • 相关文献

参考文献1

二级参考文献12

  • 1Rebecca Siegel,Deepa Naishadham,Ahmedin Jemal.Cancer statistics, 2013[J]. CA: A Cancer Journal for Clinicians . 2013 (1)
  • 2Van Cutsem E,Feyereislova A,张信华.曲妥珠单抗联合化疗与单纯化疗治疗HER2阳性晚期胃或胃食管结合部癌的Ⅲ期、开放、随机对照临床试验(ToGA试验)[J].消化肿瘤杂志(电子版).2010(03)
  • 3Charles S Fuchs,Jiri Tomasek,Cho Jae Yong,Filip Dumitru,Rodolfo Passalacqua,Chanchal Goswami,Howard Safran,Lucas Vieira dos Santos,Giuseppe Aprile,David R Ferry,Bohuslav Melichar,Mustapha Tehfe,Eldar Topuzov,John Raymond Zalcberg,Ian Chau,William Campbell,Choondal Sivanandan,Joanna Pikiel,Minori Koshiji,Yanzhi Hsu,Astra M Liepa,Ling Gao,Jonathan D Schwartz,Josep Tabernero.Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial[J].The Lancet.2014(9911)
  • 4Tom Waddell,Ian Chau,David Cunningham,David Gonzalez,Alicia Frances,Clare Okines,Andrew Wotherspoon,Claire Saffery,Gary Middleton,Jonathan Wadsley,David Ferry,Wasat Mansoor,Tom Crosby,Fareeda Coxon,David Smith,Justin Waters,Timothy Iveson,Stephen Falk,Sarah Slater,Clare Peckitt,Yolanda Barbachano.Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 5Yung-Jue Bang,Young-Woo Kim,Han-Kwang Yang,Hyun Cheol Chung,Young-Kyu Park,Kyung Hee Lee,Keun-Wook Lee,Yong Ho Kim,Sang-Ik Noh,Jae Yong Cho,Young Jae Mok,Yeul Hong Kim,Jiafu Ji,Ta-Sen Yeh,Peter Button,Florin Sirzén,Sung Hoon Noh.Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J].The Lancet.2012(9813)
  • 6Stephen R. Smalley,Jacqueline K. Benedetti,Daniel G. Haller,Scott A. Hundahl,Norman C. Estes,Jaffer A. Ajani,Leonard L. Gunderson,Bryan Goldman,James A. Martenson,J. Milburn Jessup,Grant N. Stemmermann,Charles D. Blanke,John S. Macdonald.Updated Analysis of SWOG-Directed Intergroup Study 0116: A Phase III Trial of Adjuvant Radiochemotherapy Versus Observation After Curative Gastric Cancer Resection[J].Journal of Clinical Oncology.2012(19)
  • 7Florian Lordick,Yoon-Koo Kang,Hyun-Cheol Chung,Pamela Salman,Sang Cheul Oh,Gy?rgy Bodoky,Galina Kurteva,Constantin Volovat,Vladimir M Moiseyenko,Vera Gorbunova,Joon Oh Park,Akira Sawaki,Ilhan Celik,Heiko G?tte,Helena Melezínková,Markus Moehler.Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial[J].Lancet Oncology.2013(6)
  • 8Douglas E. Guggenheim,Manish A. Shah.Gastric cancer epidemiology and risk factors[J].J Surg Oncol.2012(3)
  • 9Eric Van Cutsem,Sanne de Haas,Yoon-Koo Kang,Atsushi Ohtsu,Niall C. Tebbutt,Jian Ming Xu,Wei Peng Yong,Bernd Langer,Paul Delmar,Stefan J. Scherer,Manish A. Shah.Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial[J].Journal of Clinical Oncology.2012(17)
  • 10A.F.C. Okines,D. Gonzalez de Castro,D. Cunningham,I. Chau,R.E. Langley,L.C. Thompson,S.P. Stenning,C. Saffery,Y. Barbachano,F. Coxon,G. Middleton,D. Ferry,T. Crosby,S. Madhusudan,J. Wadsley,J. Waters,M. Hall,D. Swinson,A. Robinson,D. Smith,J.S. Reis-Filho,T.S. Waddell,L. Puckey,S. Hulkki Wilson,Z. Eltahir,M. Band,A. Wotherspoon.Biomarker analysis in oesophagogastric cancer: Results from the REAL3 and TransMAGIC trials[J].European Journal of Cancer.2013(9)

共引文献9

同被引文献93

引证文献11

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部